NCT06053541View on ClinicalTrials.gov

Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change

CompletedOBSERVATIONAL
Enrollment

3,015,000

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

July 1, 2021

Study Completion Date

July 1, 2021

Conditions
Pulmonary Disease, Chronic Obstructive
Trial Locations (1)

04794-000

Boehringer Ingelheim Brasil, São Paulo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT06053541 - Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change | Biotech Hunter | Biotech Hunter